Sage Journals: Discover world-class research

Abstract

Objective

Methotrexate and rapamycin demonstrate an additive effect in prolonging cardiac allograft survival in a major histocompatibility complex mismatched rat model. The present study aimed to identify functional proteins involved in the allograft-protective effects of these two agents and reveal potential diagnostic markers for treating rejection.

Methods

Serum samples from heterotopic heart-transplanted LEW(RT-1¹) rats (either without immunosuppressive treatment or treated with methotrexate alone, rapamycin alone, or methotrexate and rapamycin combined) were analysed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Protein profiles obtained using a weak cation exchange ProteinChip® CM-10 array were then analysed using ProteinChip® Software.

Results

Of 28 rejection-related proteins identified, isoelectric point and mass information from two potential candidate proteins matched information from the UniProtKB/Swiss-prot database, suggesting them to be complement component C3f fragment and complement component 4A (C4A, anaphylatoxin).

Conclusions

Proteomic analysis revealed 28 proteins as potential diagnostic markers of tissue rejection. Of these, 11 proteins may represent targets relating to the additive effects of methotrexate and rapamycin. Two protein peaks, with mass-to-charge ratios of 1950 Da and 8577 Da, may have potential for use in post-transplant diagnosis of rejection.

Keywords

Rejection surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)transplant complement component C3f fragment complement component 4A (C4A anaphylatoxin)

Get full access to this article

View all access options for this article.

References

Orlando

. Finding the right time for weaning off immunosuppression in solid organ transplant recipients. Expert Rev Clin Immunol 2010; 6: 879–892.

Xiu

Uchida

. Simplified method of heterotopic rat heart transplantation using the cuff technique: application to sublethal dose protocol of methotrexate on allograft survival. Microsurgery 2001; 21: 16–21.

Sakuma

Xiu

Uchida

. Short-course methotrexate and long-term acceptance of fully allogeneic rat cardiac grafts: a possible mechanism of tolerance. Transpl Immunol 2002; 10: 49–54.

Tang

Tornatore

Weinberger

. Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23: 34–44.

Issaq

Veenstra

Conrads

. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587–592.

Grus

Joachim

Pfeiffer

. Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry. Proteomics 2003; 3: 957–961.

Ono

Lindsey

. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225–229.

Petricoin

Liotta

. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24–30.

Clarke

. Proteomic research in renal transplantation. Ther Drug Monit 2006; 28: 19–22.

10.

Elased

Cool

Morris

. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 2005; 46: 953–959.

11.

Sacks

Zhou

. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12: 431–442.

12.

Brown

Kondeatis

Vaughan

. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med 2006; 354: 2014–2023.

13.

Damman

Daha

H Leuvenink

. Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant 2012; 12: 660–668.

14.

Varagunam

Yaqoob

Döhler

. C3 polymorphisms and allograft outcome in renal transplantation. New Engl J Med 2009; 360: 874–880.

15.

Nakagawa

Komorita

. Complement component C3-derived neutrophil chemotactic factors purified from exudate of rat carrageenin-induced inflammation. Biochem Biophys Res Commun 1993; 194: 1181–1187.

16.

Ganu

Müller-Eberhard

Hugli

. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. Mol Immunol 1989; 26: 939–948.

17.

Cui

Ferreri

Hugli

. Structural characterization of the C4a anaphylatoxin from rat. Mol Immunol 1988; 25: 663–671.

18.

Schifferli

Peters

. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986; 315: 488–495.

19.

Barnett

Mijovic

Fletcher

. Low plasma C4 concentrations: association with microangiopathy in insulin dependent diabetes. Br Med J (Clin Res Ed) 1984; 289: 943–945.

20.

Lappas

. Lower circulating levels of complement split proteins C3a and C4a in maternal plasma of women with gestational diabetes mellitus. Diabet Med 2011; 28: 906–911.

Proteomic profiling of heterotopic heart-transplanted rats using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry: Potential biomarkers and drug targets